Literature DB >> 18347004

The "other" signaling of trastuzumab: antibodies are immunocompetent drugs.

Luca Gianni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18347004     DOI： 10.1200/JCO.2007.15.7404

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.

Authors:  Dhara N Amin; Deepika Ahuja; Paul Yaswen; Mark M Moasser
Journal:  Mol Cancer Ther       Date:  2015-10-05       Impact factor: 6.261

Review 2.  Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.

Authors:  Fabio Puglisi; Alessandro Marco Minisini; Carmine De Angelis; Grazia Arpino
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

3.  First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Authors:  Y J Bang; G Giaccone; S A Im; D Y Oh; T M Bauer; J L Nordstrom; H Li; G R Chichili; P A Moore; S Hong; S J Stewart; J E Baughman; R J Lechleider; H A Burris
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

4.  Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.

Authors:  Mark M Moasser
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

5.  Targeting HER2 by Combination Therapies.

Authors:  Ana Ruiz-Saenz; Mark M Moasser
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

6.  Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.

Authors:  John Stagg; Janelle Sharkey; Sandra Pommey; Richard Young; Kazuyoshi Takeda; Hideo Yagita; Ricky W Johnstone; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

7.  Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.

Authors:  Gianmaria Miolo; Elena Muraro; Debora Martorelli; Davide Lombardi; Simona Scalone; Simon Spazzapan; Samuele Massarut; Tiziana Perin; Elda Viel; Elisa Comaro; Renato Talamini; Ettore Bidoli; Elisa Turchet; Diana Crivellari; Riccardo Dolcetti
Journal:  BMC Cancer       Date:  2014-12-15       Impact factor: 4.430

8.  Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.

Authors:  Marcia R Campbell; Ana Ruiz-Saenz; Yuntian Zhang; Elliott Peterson; Veronica Steri; Julie Oeffinger; Maryjo Sampang; Natalia Jura; Mark M Moasser
Journal:  Cell Rep       Date:  2022-02-01       Impact factor: 9.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.